anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Complications of ascariasis are a significant cause of abdominal pain in pediatric emergencies, especially where it is endemic. A literature review was conducted with the aim of improving diagnostic and therapeutic approaches for these patients.
DATA SOURCES: A PubMed search was conducted using the key terms "ascariasis complications" and "hepatobiliary ascariasis". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, case reports, and reviews published up to December 2023.
SUMMARY OF FINDINGS: Obstruction of the small bowel is the most common complication. Others that are, rarer and more difficult to properly identify and treat, such as biliary, hepatic, and pancreatic complications, acute appendicitis, Meckel's diverticulitis, or peritoneal granulomas. Hepatic and pancreatic complications are rarer and more serious in children than in adults. While plain radiography is usually the only option in cases of intestinal obstruction, ultrasonography is the examination of choice in cases of hepatobiliary, pancreatic, and appendicular ascariasis complications in childhood. The treatment is clinical and conservative in most patients. Surgical treatment is indicated if conservative therapy fails, or if there are signs of complications. Laparoscopy has been used as an excellent technical alternative in adults with hepatobiliary complications of ascariasis, but further studies on its use in children are still needed.
CONCLUSION: The creation of protocols and greater debate on this subject should be encouraged for a better understanding of the disease and to establish an early diagnosis and adequate treatment for children with complications resulting from massive infestation by Ascaris lumbricoides.
Participants in this condition are assigned to an empirically supported 8-week online compassion-based intervention protocol. The intervention includes a weekly 2-hour educational session and a recommendation of 15-30-mins of daily meditation, and real-world assignments to practice compassion.
We have created a simple screening tool (the "DOC" Screen) that will be routinely applied to all patients at a high-volume Regional Stroke Prevention Clinic. Consenting patients will also undergo "gold standard" research assessments in order to determine the diagnostic characteristics of the screen compared to gold standard research assessments.The proportion of eligible patients who complete DOC screening and the time for completion (mean, range, standard deviations) will be calculated from aggregated data for all new consults in the stroke prevention clinic. For patients who consented to undergo gold standard testing, sensitivity, specificity, positive predictive value, negative predictive value and likelihood ratios of the DOC screen will be calculated. Screening cut-points will be optimized using Receiver Operating Characteristic (ROC) and area under the curve analysis, and logistic regression will be applied to this ROC Curve analysis to control for variables such as age, sex, BMI and education. We hope to develop a pragmatic approach to screening the large, high-risk stroke prevention clinic population, allowing broad screening for these important health conditions. This could change routine standard of care across stroke prevention clinics and facilitate early identification and appropriate assessment of patients.
Ischemic conditions such as hypoxia and nutrient starvation, together with interactions with stromal cells, are critical drivers of metastasis. These conditions arise deep within tumor tissues, and thus, observing nascent metastases is exceedingly challenging. We thus developed the 3MIC-an ex vivo model of the tumor microenvironment-to study the emergence of metastatic features in tumor cells in a 3-dimensional (3D) context. Here, tumor cells spontaneously create ischemic-like conditions, allowing us to study how tumor spheroids migrate, invade, and interact with stromal cells under different metabolic conditions. Consistent with previous data, we show that ischemia increases cell migration and invasion, but the 3MIC allowed us to directly observe and perturb cells while they acquire these pro-metastatic features. Interestingly, our results indicate that medium acidification is one of the strongest pro-metastatic cues and also illustrate using the 3MIC to test anti-metastatic drugs on cells experiencing different metabolic conditions. Overall, the 3MIC can help dissecting the complexity of the tumor microenvironment for the direct observation and perturbation of tumor cells during the early metastatic process.
Disclosed herein is a cleaning device for orthokeratology lens, comprising a housing, a cap, a gear module, two cleaning shaft, two cleaning head, and a rotating shaft. The housing comprises two orthokeratology lens bases and an opening. The cap is disposed on the opening. The cleaning shaft comprises a first end connecting to the gear module and a second end. The cleaning head is disposed on the second end of the cleaning shaft. The rotating shaft connects to the gear module.
Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing. ONJ has been reported in patients receiving denosumab [see Adverse Reactions (6.1)]. A routine oral exam should be performed by the prescriber prior to initiation of Prolia treatment. A dental examination with appropriate preventive dentistry is recommended prior to treatment with Prolia in patients with risk factors for ONJ such as invasive dental procedures (e.g. tooth extraction, dental implants, oral surgery), diagnosis of cancer, concomitant therapies (e.g. chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and comorbid disorders (e.g. periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures). Good oral hygiene practices should be maintained during treatment with Prolia. Concomitant administration of drugs associated with ONJ may increase the risk of developing ONJ. The risk of ONJ may increase with duration of exposure to Prolia.

For patients requiring invasive dental procedures, clinical judgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit-risk assessment.

Patients who are suspected of having or who develop ONJ while on Prolia should receive care by a dentist or an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of Prolia therapy should be considered based on individual benefit-risk assessment.
PURPOSE: Bowel dysfunction after sphincter-preserving-surgery (SPS) impacts quality of life. The Wexner score (WS) and the low anterior resection syndrome (LARS) score (LS) are instruments for assessing postoperative bowel dysfunction. We analyzed the incidence of and risk factors for each symptom and examined the discrepancies between the two scores.
METHODS: A total of 142 patients with rectal cancer, who underwent minimally invasive SPS between May, 2018 and July, 2019, were included. A questionnaire survey using the two scores was given to the patients 2 years after SPS.
RESULTS: Tumor location and preoperative radiotherapy were independent risk factors for major LARS. Intersphincteric resection with a hand-sewn anastomosis (HSA) was an independent risk factor for high WS. Among the patients who underwent HSA, 82% experienced incontinence for liquid stools, needed to wear pads, and suffered lifestyle alterations. Of the 35 patients with minor LARS, only 1 had a high WS, and 80.0% reported no lifestyle alterations. Among the 75 patients with major LARS, 58.7% had a low WS and 21.3% reported no lifestyle alterations.
CONCLUSION: The results of this study provide practical data to help patients understand potential bowel dysfunction after SPS. The discrepancies between the WS and LS were clarified, and further efforts are required to utilize these scores in clinical practice.
Maintaining patient safety, ensuring best patient outcomes, and optimal pain relief post-operatively are of utmost concern for anesthesia providers. Adequate pain relief attenuates stress responses and long-term chronic pain complications while contributing to improved postoperative outcomes.

Knee arthroscopy is a very common procedure and very often is performed as day-case surgery. Ambulatory arthroscopic surgery of the knee is preferred by the majority of properly selected and well-informed patients. It has been reported that a significant number of patients have moderate to severe pain 24 hours after ambulatory surgery in general and knee arthroscopy in particular and pain affects the patient's activity level and satisfaction. Adductor canal block (ACB) is a popular peripheral nerve block that has been shown to decrease the pain significantly and decrease opioid consumption with minimal effect on quadriceps function. It provides analgesia to the peri-articular and intra-articular aspects of the knee joint but doesn't relieve posterior knee pain which is moderate to severe in intensity.
Patient with HNSCC or STS with surface accessible lesions who are scheduled for tumor or regional node dissection as part of their standard treatment will be injected two to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of pembrolizumab as a single agent or in combination with MK-0482 or MK-4830. Each microdose is simultaneously injected in a columnar fashion through each of 5 or 8 needles by the CIVO Micodose Injection Device (MID) into a single solid tumor or effaced metastatic lymph node.
Cellulite is a skin condition that significantly affects women, characterized by "holes" or depressions in the skin, affecting approximately 95% of women at some point in their lives. Cellulite often presents inflammatory symptoms such as increased skin temperature and hyperalgesia. Photobiomodulation, whether applied locally or systemically, has demonstrated important anti-inflammatory effects in various conditions. This study investigates the effects of local and systemic photobiomodulation on hip culottes temperature increases and hyperalgesia in patients with grades 2 to 4 cellulite. Cellulite assessment was carried out using detailed anamnesis, photographic records, algometry, and infrared thermography. Participants received randomized bilateral treatment with or without systemic irradiation using LED photobiomodulation on the hip culottes for four weeks, three times a week. This study aimed to evaluate the effect of photobiomodulation, especially locally applied, together or not with systemic irradiation, on cellulite hyperalgesia and skin temperature among 25 female participants. The group that received only LED treatment showed an increase in pain threshold of 8% and 20% on the right and left sides, respectively, while the group treated with LED + ILIB showed an increase in pain threshold of 32% on both sides. Local photobiomodulation produced a skin temperature decrease of 0.4 °C, while the combination of local and systemic irradiation produced an average skin temperature decrease of 1.2 °C. Our results clearly demonstrate a significantly beneficial effect of LED therapy for cellulite treatment, especially when administered in combination with mILIB, leading to a significant reduction of pain hypersensitivity and skin temperature, indicating a regional subcutaneous improvement of the inflammatory status.
FIELD: chemistry. ^ SUBSTANCE: invention relates to methods of preparing a concentrate of silver oxides and can be used in making highly effective preparations in medicine and veterinary science. The method involves pouring distilled water at 80C into a chemically clean glass vessel, immersing a silver ion source holder into the water, connecting a direct current circuit and stirring the solution after appearance of electrical conductivity detected by a milliamperemetre. Stirring is repeated several times before appearance of excess concentration of silver ions in form of a brown, then black colloidal solution. The process is stopped when electrical conductivity falls. Silver oxides are removed from the electrodes into a prepared solution. The remaining solution cooled to room temperature is then separated in a centrifuge. The purified solution is then recycled and the precipitate with a small amount of water is poured into a container made from dark glass with minimal air space for subsequent storage. ^ EFFECT: obtaining a concentrate of silver (I) oxide which can be used to prepare a solution of silver ions for medical preparations by dissolving in distilled water and filtration of insoluble silver oxides. ^ 2 cl
A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound. A method of treating multiple disease causes, by administering a glycocalyx restoring and maintaining compound to an individual, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage. A method of treating cardiovascular disease. A method of restoring the glycocalyx. A method of reversing inflammation. A method of reversing oxidative damage. A method of treating any disease involving a membrane that has a glycocalyx. A method of treating multiple disease causes. A method of restoring the structural and functional integrity of receptors in the glycocalyx. A method of restoring the glycocalyx and receptors therein and potentiating drug response. A composition for treating disease including the glycocalyx restoring and maintaining compound and an antibody. A composition for treating cardiovascular disease including the glycocalyx restoring and maintaining compound and a MAb anti-PCSK9.
This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
The present disclosure relates to cell culture type adipose tissue. In one embodiment, the cultured adipose tissue is produced by culturing adipocytes in an in vitro medium, harvesting the adipocytes after producing the desired amount of adipocytes, and aggregating the harvested adipocytes to provide the cultured adipose tissue. In some embodiments, aggregating the harvested adipocytes comprises mixing the harvested adipocytes with a hydrogel or binder in a three-dimensional (3D) mold. In other embodiments, aggregating the harvested adipocytes comprises cross-linking the harvested adipocytes in a 3D mold. Cultured adipose tissue has a defined 3D shape and dimensions on a macroscopic scale. In some embodiments, the cultured adipose tissue may be a food product.
This is a phase 2 study of extracorporeal photopheresis (ECP) for treatment of chronic graft versus host disease following allogeneic hematopoietic stem cell transplantation. Extracorporeal exposure of human mononuclear cells to ultraviolet A radiation following photosensitization with 8-methoxypsoralen has proven to be an effective treatment for cutaneous T-cell lymphoma. Small, single institution studies have suggested efficacy in other T-cell mediated diseases such as solid organ rejection and graft versus host disease. This a phase 2 study of ECP for treatment of chronic graft versus host disease. Eligible patients must have objective evidence of chronic graft versus host disease that is refractory to conventional therapy or must have steroid-dependent disease that does not permit steroid dose reduction. The primary objective of this study is to better define the safety, efficacy and mechanism of action of ECP for treatment of patients with chronic graft versus host disease.
A method includes capturing a first image of a medicament contained by a receptacle. The method includes creating a second image based on the first image. The method includes determining a first subset of pixels of a second image that are more likely to correspond to the receptacle. The method comprises processing the second image along the first axis by, for each point: defining a line that perpendicularly intersects the first axis at the point, and counting how many pixels located along the line are in the first subset. The method includes determining first and second local maxima of the count. The method includes estimating the positions of the first and second edges of the receptacle based on the position of the local maximum. The method comprises defining an ellipse based on the first edge and the second edge, and excluding regions of the first image outside the defined ellipse by further processing.
Patient pre-screening is facilitated through a system of hierarchically linked catalogues, each comprising at least one condition-descriptive entry. The hierarchy of linked catalogues is essentially tree structure in which the content of the lower-level catalogues is dependent upon particular entries in upper-level catalogues. In one embodiment, the uppermost catalogue comprises a model display of a male or female. In general, a condition-descriptive entry from an uppermost catalogue is selected. The selected condition-descriptive entry from the uppermost catalogue determines at least one lower-level catalogue that is subsequently displayed By traversing the linked catalogues in this manner, a concise diagnosis or symptom description may be quickly and accurately generated. In one embodiment of the present invention, diagnoses arrived at through the hierarchical structure include an ICS-9 code, thereby facilitating implementations of databases.
The high protein weight loss group follows the Medifast 4 \& 2 \& 1 Plan™, a 1200 calorie, high protein diet targeting \~10% weight loss over 24-weeks through a combination of meal replacement products (MRPs), meal plans, and individual nutrition/behavioral counseling. Participants are guided by the study RD on food purchasing and preparation and encouraged to consume only what is approved from the menu. Participants meet bi-weekly for RD-lead behavioral counseling group classes to provide support and introduce new topics in behavioral weight control. Weight is also measured at each session with progress feedback provided to increase motivation. Participants complete daily food logs to verify compliance to the diet.
Group that includes adult patients under study. Those with mild TBI will be recruited. In order to determine the severity of the mild TBI, the doctor uses a scale called the Glasgow GCS scale and mild TBI is understood as those with GCS: 14-15.
Certain carbocyanine (carbocyanine) compounds target mitochondria and are useful for eradicating Cancer Stem Cells (CSCs). For example, mitoTracker Deep Red (MTDR) is a non-toxic, carbocyanine-based far infrared fluorescent probe commonly used for chemical labeling and visualization of mitochondria in living cells. MTDR inhibits 3D glomerular formation in MCF7 cells, MDA-MB-231 cells and MDA-MB-468 cells with an IC-50 of 50nM to 100nM. Furthermore, at the level of 500nM, MTDR almost completely inhibited mitochondrial oxygen consumption rate and ATP production in all three breast cancer cell lines tested. Nanomolar concentrations of MTDR can be used to specifically target and eradicate CSCs by selectively interfering with mitochondrial metabolism. Other carbocyanine compounds having anti-CSC activity are described.
The pattern and incidence of adverse events and laboratory abnormalities recorded during pediatric clinical trials are comparable to those seen in adults.

In Phase II/III clinical trials conducted in the United States and in Europe, 577 pediatric patients, ages 1 day to 17 years were treated with fluconazole at doses up to 15 mg/kg/day for up to 1,616 days. Thirteen percent of children experienced treatment- related adverse events. The most commonly reported events were vomiting (5%), abdominal pain (3%), nausea (2%), and diarrhea (2%). Treatment was discontinued in 2.3% of patients due to adverse clinical events and in 1.4% of patients due to laboratory test abnormalities. The majority of treatment-related laboratory abnormalities were elevations of transaminases or alkaline phosphatase.

To report suspected ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-800-308-6755 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The invention belongs to the field of biological medicine, and relates to an anti-PVRIG antibody. In particular, the invention relates to an anti-PVRIG antibody or antigen binding fragment thereof, wherein the antibody comprises a heavy chain variable region comprising HCDR1 to HCDR3 and a light chain variable region comprising LCDR1 to LCDR3, wherein: the heavy chain variable region of the antibody, the amino acid sequence of HCDR1 is shown as SEQ ID NO. 9, the amino acid sequence of HCDR2 is shown as SEQ ID NO. 10, the amino acid sequence of HCDR3 is shown as SEQ ID NO. 11, the light chain variable region of the antibody, the amino acid sequence of LCDR1 is shown as SEQ ID NO. 12, the amino acid sequence of LCDR1 is shown as SEQ ID NO. 13, and the amino acid sequence of LCDR1 is shown as SEQ ID NO. 14. The antibody provided by the invention has higher affinity with PVRIG, even has synergistic effect with anti-TIGIT monoclonal antibody and/or anti-PD-1 antibody, and has good anti-tumor application prospect.
Gefitinib has been tested for genotoxicity in a series of in vitro (bacterial mutation, mouse lymphoma, and human lymphocyte) assays and an in vivo rat micronucleus test. Under the conditions of these assays, gefitinib did not cause genetic damage. 

In a two-year carcinogenicity study in mice, administration of gefitinib at a dose of 270 mg/m2/day (approximately twice the recommended daily dose of 250 mg on a mg/m2 basis; dose reduced from 375 mg/m2/day from week 22) caused hepatocellular adenomas in females. In a two-year carcinogenicity study in rats, administration of gefitinib at 60 mg/m2/day (approximately 0.4 times the recommended daily clinical dose on a mg/m2 basis) caused hepatocellular adenomas and hemangiomas/hemagiosarcomas of the mesenteric lymph nodes in female rats. The clinical relevance of these findings is unknown.

In a dedicated fertility study in rats at doses ≥120 mg/m2 (approximately equal to the recommended human dose of gefitinib on a mg/m2 basis), animals presented with an increased incidence of irregular estrous, decreased corpora lutea, and decreases in uterine implants and live embryos per litter.